What is Peptide bioregulators (Khavinson peptides)?
Peptide bioregulators are very short synthetic peptides, two to four amino acids long, developed by Vladimir Khavinson and colleagues in St. Petersburg. Each is named for the tissue it was proposed to support. Almost all published research on them comes from that group and its collaborators.
Biological role or research focus
Gene-expression and aging research, mostly from one research group.
The evidence is concentrated in one research network, much of it in Russian-language journals, with few independent replications and few controlled human trials. A narrative review by the originating group is not a systematic review, and seller product names may not match the exact compounds studied.
Role reference: Peptide Regulation of Cell Differentiation · 2020 ↗
Names you may encounter
Khavinson peptides · Short peptide bioregulators · Bronchogen · Cardiogen · Cartalax · Chonluten · Cortagen · Livagen · Ovagen · Pancragen · Prostamax · Testagen · Thymogen · Thymagen · Vesilute · Vesugen · Vilon
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Family of synthetic two- to four-amino-acid peptides developed at the St. Petersburg Institute of Bioregulation and Gerontology
- Research focus
- Gene-expression and aging research, mostly from one research group
- Featured evidence
- Review by the originating research group
- Source check
- October 4, 2026
Quick answers
- Is Peptide bioregulators (Khavinson peptides) FDA approved?
- No. No FDA-approved drug contains Peptide bioregulators (Khavinson peptides). Source ↗
- Is Peptide bioregulators (Khavinson peptides) safe?
- Not FDA-approved. Short 'bioregulator' peptides come mainly from one Russian research network; small human reports exist for a few, but safety has not been tested to modern standards. Human safety data: very limited. The Risks & interactions section below lists what is known. Read the risks ↓
- Is Peptide bioregulators (Khavinson peptides) banned in sport?
- Very likely. The 2026 World Anti-Doping Agency (WADA) Prohibited List does not name it, but it appears to fall under a banned class (S0 Non-approved substances). Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| Review: short peptides and cell differentiation (2020) | Review by the originating research group | Cell cultures, tissue explants and laboratory animals, as summarized by the originating research group. |
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Review by the originating research group · 2020
Review: short peptides and cell differentiation
What did this publication test, and what did it find?
- Population / model
- Cell cultures, tissue explants and laboratory animals, as summarized by the originating research group.
- Study design
- Narrative review of the group's own and related research on short peptides and stem-cell or tissue-cell differentiation.
- Main finding
- The review reports that particular short peptides were associated with differentiation of nerve, lung, pancreatic, immune and bone-forming cells in laboratory models, and describes proposed gene and chromatin mechanisms.
- Limits & context
- The evidence is concentrated in one research network, much of it in Russian-language journals, with few independent replications and few controlled human trials. A narrative review by the originating group is not a systematic review, and seller product names may not match the exact compounds studied.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
1 registered study names Peptide bioregulators (Khavinson peptides) as an intervention; 0 are recruiting or under way, 0 have not started recruiting yet and 1 completed. Checked November 16, 2026 on ClinicalTrials.gov.
| Study | Status | Phase | Start | People |
|---|---|---|---|---|
| Prospective Evaluation of Strontium in Patients After CardioGen-82 PET MPI Scanning NCT01424774 · Bracco Diagnostics, Inc | Completed | 2011-09 | 155 |
A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination.
Search additional PubMed records ↗Risks & interactions
Not FDA-approved. Short 'bioregulator' peptides come mainly from one Russian research network; small human reports exist for a few, but safety has not been tested to modern standards.
Small Russian clinical reports exist for some members (such as thymalin and pinealon), mostly without clear randomization or blinding. Research-grade products are not tested as medicines, and seller names may not match studied compounds.
Unassessed: little human safety data
It isn't approved, so there is no official list of who should avoid it, and its human studies are too small to show who is most at risk. No condition is tagged, but that does not make it safe for anyone. If a condition applies to you, talk to a doctor or pharmacist first.
Who should not use it
There is no official list, because it has never been approved as a medicine. That is not a sign it is safe for anyone: its risks have not been studied enough to know who is most at risk.
Summarized from published studies with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: Peptide regulation of cell differentiation (review, 2020) ↗ · Peptides of pineal gland and thymus prolong human life (2003) ↗ · Synthetic peptides in patients with chronic polymorbidity (2015) ↗
Safety & what remains unknown
Formal human safety data are limited. Small Russian clinical reports exist for some members, but they do not establish safety to modern trial standards, and research-grade vials are not tested as medicines.
Source: Peptide Regulation of Cell Differentiation · 2020 ↗
Evidence boundaries
The evidence is concentrated in one research network, much of it in Russian-language journals, with few independent replications and few controlled human trials. A narrative review by the originating group is not a systematic review, and seller product names may not match the exact compounds studied.
Source: Peptide Regulation of Cell Differentiation · 2020 ↗
Regulatory status
- U.S. FDA approval
- Not approved
No FDA-approved drug containing this substance found in Drugs@FDA (openFDA data updated 2026-10-07). source - FDA compounding (503A bulk list)
- Not on FDA’s compounding lists
Not found on FDA's 503A category 1, 2 or 3 lists (updated May 14, 2026) or the category 2 safety-risk page (updated April 22, 2026). source - World Anti-Doping Agency (2026)
- Likely prohibited under a class rule · S0 Non-approved substances
Not named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered. Individual products vary; some short peptides in this group are reported to be registered as medicines in Russia (not verified here), which would take those specific products outside S0. source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Research context & identity
This profile groups the members of the family that sellers list, because separate pages would mostly repeat the same small evidence base. Epitalon, Pinealon and Thymalin have their own profiles.
Sequences stated in published abstracts: Bronchogen (Ala-Glu-Asp-Leu, studied in lung and bronchial tissue), Cortagen (Ala-Glu-Asp-Pro), Livagen (Lys-Glu-Asp-Ala, liver), Pancragen (Lys-Glu-Asp-Trp, pancreas), Testagen (Lys-Glu-Asp-Gly) and Vilon (Lys-Glu). Cardiogen, Chonluten, Prostamax, Thymogen (sold as Thymagen) and Vesugen appear in the literature, but the abstracts checked did not state their sequences. Cartalax and Vesilute had no indexed publications. In PubMed, "Ovagen" refers to an unrelated veterinary follicle-stimulating hormone product, so a seller's "Ovagen peptide" could not be matched to any study.
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
Seller lab-report checks and prices are available to members. Sign up free
Biology & proposed mechanism
The group proposes that these short peptides enter cells and nuclei and influence gene activity, including genes for cell differentiation, partly by interacting with DNA and histones. Their 2020 review summarizes cell, tissue and animal work; for example, it reports that AEDL (Bronchogen) and KEDW (Pancragen) promoted lung and pancreatic cell differentiation. These mechanisms come mainly from laboratory models and have rarely been tested independently.
Questions worth asking
- Why are 14 products covered on one page?
- What material, population, and route were actually studied?
- The evidence is concentrated in one research network, much of it in Russian-language journals, with few independent replications and few controlled human trials. A narrative review by the originating group is not a systematic review, and seller product names may not match the exact compounds studied.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Video & podcast discussions: members library
Frequently asked questions
Why are 14 products covered on one page?
They share one origin, one proposed mechanism and one small, mostly single-group evidence base. One page states those shared limits clearly, and it notes which names have a sequence confirmed in published abstracts.
Does the publication verify a supplier’s product?
No. The tested material and a commercial listing need separate identity and batch checks. A research-use disclaimer does not establish clinical suitability.
References & editorial record
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
